CE Opioid Prescribing Pain CME

Guideline recommendations

• Identify the key recommendations of the 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain including the shift from rigid dose thresholds to individualized assessment.
• Explain the CDC recommendations for initiating opioid therapy for acute pain including preferred duration limits, immediate-release formulations, and lowest effective dose principles.
• Describe the CDC recommendations for ongoing opioid therapy assessment including periodic reassessment of benefits and risks, functional outcome evaluation, and optimization of non-opioid treatments.
• Analyze the evolution from the 2016 to 2022 CDC opioid guidelines and evaluate how the updated recommendations address unintended consequences of rigid dose ceiling interpretations.

Guideline implementation

• Identify barriers to implementing CDC opioid prescribing guidelines including clinician time constraints, patient expectations, payer policies, and state law misalignment.
• Evaluate the balance between guideline adherence and individualized patient care for complex chronic pain patients including those with co-occurring mental health conditions.
• Design a clinical workflow for implementing CDC opioid prescribing guidelines in a primary care practice including decision support tools, documentation templates, and quality metrics.
• Analyze the role of state opioid prescribing laws and regulations in shaping clinical practice and identify where state requirements exceed or conflict with CDC guideline recommendations.

Risk assessment tools

• Identify validated opioid risk assessment tools including the Opioid Risk Tool, SOAPP-R, DIRE score, and the Brief Risk Interview and describe their intended clinical applications.
• Explain the risk factors assessed by the Opioid Risk Tool including personal and family history of substance abuse, age, psychological conditions, and preadolescent sexual abuse.
• Describe the limitations of opioid risk assessment tools including sensitivity and specificity tradeoffs, population validation gaps, and the risk of bias in clinical application.

Risk-stratified management

• Analyze patient risk profiles to determine appropriate monitoring intensity including visit frequency, urine drug screening intervals, prescription quantity limits, and pill count schedules.
• Evaluate aberrant medication-related behaviors to distinguish between pseudoaddiction, substance use disorder, and criminal diversion and determine appropriate clinical responses.
• Design a risk-stratified opioid monitoring protocol that assigns patients to low, moderate, or high risk categories with corresponding monitoring plans, treatment agreements, and escalation triggers.
• Identify the components of an opioid treatment agreement including patient responsibilities, prescriber commitments, urine drug screening consent, single-prescriber provisions, and termination criteria.

Testing methodology

• Identify the types of urine drug testing including point-of-care immunoassay screening and laboratory confirmatory testing with GC-MS or LC-MS/MS and the clinical role of each.
• Explain the limitations of immunoassay urine drug screening including cross-reactivity, false positives from common medications, detection windows, and the inability to detect synthetic opioids.
• Describe expected metabolite patterns for commonly prescribed opioids and explain how the presence or absence of expected metabolites informs compliance assessment.

Result interpretation and action

• Analyze unexpected urine drug screening results including absent prescribed medications, presence of non-prescribed substances, and inconsistent metabolite patterns.
• Evaluate the appropriate clinical response to abnormal urine drug screens including confirmatory testing, patient conversation approaches, treatment plan modification, and documentation.
• Identify specimen validity testing parameters including creatinine concentration, pH, temperature, specific gravity, and oxidant testing to detect specimen tampering or substitution.
• Design a urine drug screening protocol for an opioid prescribing practice that addresses testing frequency, panel selection, result interpretation algorithms, and patient communication scripts.

Regulatory and pharmacologic basis

• Identify the regulatory changes affecting buprenorphine prescribing including DATA 2000, CARA 2016, the SUPPORT Act, MATE Act training requirements, and the 2023 X-waiver elimination.
• Explain buprenorphine pharmacology including partial mu-opioid agonist properties, ceiling effect on respiratory depression, high receptor binding affinity, and the rationale for naloxone combination.
• Describe buprenorphine formulations available for office-based treatment including sublingual tablets, sublingual film, buccal film, and extended-release subcutaneous injection.

Clinical application

• Analyze traditional buprenorphine induction protocols including the Clinical Opiate Withdrawal Scale assessment, timing after last opioid use, initial dosing, and dose titration schedules.
• Evaluate micro-dosing (Bernese method) buprenorphine induction strategies and their advantages for patients who cannot tolerate traditional withdrawal-based induction approaches.
• Identify common barriers to buprenorphine prescribing in primary care including stigma, workflow integration, insurance prior authorization, and pharmacy stocking challenges.
• Design a primary care buprenorphine prescribing program including patient screening, induction protocols, stabilization and maintenance dosing, drug interaction monitoring, and referral criteria.

Tapering indications and planning

• Identify the clinical indications for opioid dose reduction or discontinuation including lack of functional improvement, adverse effects, aberrant behaviors, and patient request.
• Explain the principles of gradual opioid tapering including recommended reduction rates, individualized pace adjustments, and the difference between voluntary and involuntary tapers.
• Describe opioid withdrawal symptoms and their timeline and explain adjunctive medications for managing withdrawal including clonidine, loperamide, and hydroxyzine.

Tapering implementation

• Analyze patient-specific factors that influence taper rate selection including current dose, duration of opioid therapy, co-occurring conditions, and psychosocial support availability.
• Evaluate the risks of rapid involuntary opioid discontinuation including increased overdose risk from loss of tolerance, transition to illicit opioids, and mental health crisis.
• Identify the patient communication strategies for discussing opioid tapering including motivational approaches, shared decision-making, addressing fear and anxiety, and setting realistic expectations.
• Design an individualized opioid tapering protocol that includes baseline assessment, reduction schedule, withdrawal monitoring, non-opioid pain management augmentation, and outcome measurement.

Non-opioid pharmacotherapy

• Identify non-opioid pharmacologic options for pain management including NSAIDs, acetaminophen, gabapentinoids, SNRIs, tricyclic antidepressants, topical agents, and muscle relaxants.
• Explain the mechanism of action and evidence base for gabapentin and pregabalin in neuropathic pain and the emerging concerns about gabapentinoid misuse and scheduling changes.
• Describe the role of duloxetine and other SNRIs in chronic pain management including FDA-approved pain indications, dosing, and their dual benefit for co-occurring depression and anxiety.
• Analyze the comparative effectiveness of non-opioid pharmacotherapy versus opioids for common chronic pain conditions including low back pain, osteoarthritis, and fibromyalgia.

Non-pharmacologic and integrative approaches

• Identify evidence-based non-pharmacologic pain treatments including physical therapy, cognitive behavioral therapy for pain, mindfulness-based stress reduction, and exercise therapy.
• Explain the role of interventional pain procedures including epidural steroid injections, nerve blocks, radiofrequency ablation, and spinal cord stimulation in the multimodal pain framework.
• Evaluate the evidence for complementary and integrative approaches to pain management including acupuncture, chiropractic care, massage therapy, and their appropriate role in treatment plans.
• Design a comprehensive multimodal pain management plan for a patient transitioning from opioid monotherapy that integrates pharmacologic, physical, psychological, and interventional approaches.

MME calculations

• Identify the morphine milligram equivalent conversion factors for commonly prescribed opioids including hydrocodone, oxycodone, hydromorphone, fentanyl patches, and methadone.
• Explain the concept of incomplete cross-tolerance and the clinical importance of dose reduction when rotating between opioids to prevent overdose.
• Describe the unique pharmacokinetic properties of methadone including variable half-life, QTc prolongation risk, and the non-linear relationship between methadone dose and MME at higher doses.

Opioid rotation practice

• Analyze clinical scenarios requiring opioid rotation and calculate the new opioid dose using equianalgesic tables with appropriate cross-tolerance reduction factors.
• Evaluate the total daily MME for patients on multiple opioid formulations and determine whether the cumulative dose exceeds risk thresholds requiring enhanced monitoring.
• Design a clinical decision support tool for opioid dose calculations that integrates MME conversion, cross-tolerance reduction, renal and hepatic dose adjustments, and risk threshold alerts.

Documentation standards

• Identify the documentation elements required for opioid prescribing including pain assessment, functional status, treatment plan, informed consent, PDMP review, and risk assessment results.
• Explain the role of functional outcome measures in opioid therapy evaluation including validated tools for pain interference, physical function, and quality of life assessment.
• Describe the MATE Act training requirements for DEA-registered prescribers including the 8-hour training mandate, approved training sources, and the conditions-of-registration enforcement mechanism.

Legal and ethical considerations

• Analyze the legal risks of opioid prescribing including malpractice liability for both under-treatment and over-prescribing and the evolving standards of care in pain management.
• Evaluate the ethical tensions in opioid prescribing between the duty to treat pain, the obligation to prevent harm, patient autonomy, and the public health impact of the opioid epidemic.
• Identify the circumstances under which patient dismissal from an opioid prescribing practice is appropriate and the ethical and legal obligations for care continuity during transition.
• Analyze the impact of pharmacy benefit restrictions, prior authorization requirements, and formulary limitations on opioid prescribing decisions and patient access to pain treatment.
• Design a comprehensive opioid prescribing quality improvement program including prescriber education, policy development, outcome tracking, peer review, and regulatory compliance monitoring.

Identify the CDC and FDA recommendations for naloxone co-prescribing with opioids including patient risk factors, dose thresholds, and formulation options for patient and caregiver use.

Explain patient and caregiver education for naloxone use including recognizing overdose symptoms, administration technique for intranasal and intramuscular formulations, and post-administration steps.

Analyze prescribing patterns to identify patients who should receive naloxone co-prescriptions based on MME thresholds, concurrent benzodiazepine use, and substance use disorder history.

Design a clinical workflow for routine naloxone co-prescribing that integrates risk assessment, electronic health record alerts, patient education, and pharmacy coordination.